CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
On Wednesday, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.
週三，美國疾病控制與預防中心（CDC）的免疫實踐諮詢委員會（ACIP）投票建議所有75歲及以上的成年人常規使用呼吸道合胞病毒（RSV）疫苗。
The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions.
該小組還建議對60-74歲的成年人進行呼吸道合胞病毒免疫接種，他們患有嚴重呼吸道合胞病毒疾病的風險增加，這意味着他們患有某些慢性病。
The recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine.
該建議適用於去年未接種呼吸道合胞病毒疫苗的成年人。呼吸道合胞病毒疫苗目前不是年度疫苗。
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data become available.
在獲得更多數據之前，ACIP推遲了對針對50-59歲成年人RSV-LRTD風險較高的建議的投票。
GSK Plc (NYSE:GSK) says it continues to generate data.
葛蘭素史克公司（紐約證券交易所代碼：GSK）表示將繼續生成數據。
The updated recommendation for people 60 and older replaces last year's recommendation to simplify RSV vaccine decision-making for clinicians and the public.
針對60歲及以上人群的最新建議取代了去年的建議，旨在簡化臨床醫生和公衆的呼吸道合胞病毒疫苗決策。
Earlier this month, the FDA expanded the approval of GSK's Arexvy for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years at increased risk, becoming the first and only vaccine FDA-approved for adults aged 50-59 who are at increased risk for RSV-LRTD.
本月早些時候，美國食品藥品管理局擴大了葛蘭素史克Arexvy的批准範圍，用於預防風險較高的50至59歲成年人的呼吸道合胞病毒下呼吸道疾病（LRTD），成爲美國食品藥品管理局批准的第一種也是唯一一種適用於50-59歲RSV-LRTD風險較高的成年人的疫苗。
In the U.S., the vaccine was approved for use in adults aged 60 and older.
在美國，該疫苗獲准用於60歲及以上的成年人。
In April, Pfizer Inc (NYSE:PFE) released top-line immunogenicity and safety data from Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe RSV-LRTD.
4月，輝瑞公司（紐約證券交易所代碼：PFE）發佈了MoNet三期試驗的主要免疫原性和安全性數據，評估了18至59歲有發生嚴重RSV-LRTD風險的成年人使用單劑量的Abrysvo對比安慰劑。
Citing JP Morgan analyst, Reuters highlights, "We believe consensus Arexvy forecasts may now be lowered to reflect a smaller eligible U.S. patient population, confirmed Moderna Inc (NASDAQ:MRNA) competition, and more risk around GSK's two-year revaccination interval."
路透社援引摩根大通分析師的話強調說：“我們認爲，Arexvy的共識預測現在可能會下調，以反映符合條件的美國患者人數減少，Moderna Inc（納斯達克股票代碼：MRNA）的競爭得到證實，以及葛蘭素史克兩年重新接種間隔的風險增加。”
The report also added, "The decision is a negative for GSK, which makes the Arexvy RSV vaccine."
該報告還補充說：“這個決定對生產Arexvy RSV疫苗的葛蘭素史克來說是負面的。”
Also Read: Why Is Moderna Stock Trading Lower On Wednesday?
另請閱讀： 爲什麼 Moderna 股票週三交易價格走低？
Price Action: GSK shares are down 1.80% at $38.15 during the premarket session at the last check on Thursday.
價格走勢：葛蘭素史克股價在週四的最後一次盤前交易中下跌1.80％，至38.15美元。
Photo by JHVEPhoto on Shutterstock
照片由 JHVEPhoto 在 Shutterstock 上拍攝